Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367

Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus

Andraud, M., Lejeune, O., Musoro, J. Z., Ogunjimi, B., Beutels, P., & Hens, N. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002418 · Cited by 75

Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients

Chang, S., Wang, J., Huang, L., Chen, Y., Fang, C., Sheng, W., Wang, J., Yu, C., & Yang, P. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.12.1455-1457.2005 · Cited by 32

Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection

Gray, A., Martin‐Blais, R., Tobin, N. H., Wang, Y., Brooker, S. L., Li, F., Gadoth, A., Elliott, J. E., Faure-Kumar, E., Halbrook, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259703 · Cited by 18

Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants

Ibarrondo, F. J., Hofmann, C., Ali, A., Ayoub, P., Kohn, D. B., & Yang, O. O. (2021) · mBio · doi:10.1128/mbio.02656-21 · Cited by 17

Praemonitus praemunitus: can we forecast and prepare for future viral disease outbreaks?

Sessions, Z. L., Bobrowski, T., Martin, H., Beasley, J.-M. T., Kothari, A., Phares, T., Li, M., Alves, V. M., Scotti, L., Moorman, N. J., et al. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad048 · Cited by 19

Patients with Long COVID continue to experience significant symptoms at 12 months and factors associated with improvement: A prospective cohort study in France (PERSICOR)

Salmon, D., Slama, D., Linard, F., Dumesges, N., Baut, V. L., Hakim, F., Oustric, P., Seyrat, E., Thoreux, P., & Marshall, E. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.038 · Cited by 18

Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice

Fisher, E., Padula, L., Podack, K., O’Neill, K. E., Seavey, M. M., Jayaraman, P., Jasuja, R. R., & Štrbo, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.602254 · Cited by 18

Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers

Mulchandani, R., Taylor-Philips, S., Jones, H. E., Ades, A. E., Borrow, R., Linley, E., Kirwan, P., Stewart, R., Moore, P., Boyes, J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.019 · Cited by 18

Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors

Goto, A., Go, H., Miyakawa, K., Yamaoka, Y., Ohtake, N., Kubo, S., Jeremiah, S. S., Mihara, T., Senuki, K., Miyazaki, T., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.661187 · Cited by 18

Trends of new-onset psychosis or mania in psychiatric emergency departments during the COVID19 pandemic: a longitudinal comparative study

Segev, A., Klein, E. H., Kotz, G., Kamhi-Nesher, S., Halimi, S., Qashu, K., Schreiber, E., & Krivoy, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00310-w · Cited by 17

The race for a COVID-19 vaccine: where are we up to?

Hossain, M. K., Hassanzadeganroudsari, M., Feehan, J., & Apostolopoulos, V. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2021074 · Cited by 17

Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Kannenberg, J., Trawinski, H., Henschler, R., Buhmann, R., Hönemann, M., & Jassoy, C. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac034 · Cited by 20

Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccinePreprint

Gauttier, V., Morello, A., Girault, I., Mary, C., Belarif, L., Desselle, A., Wilhelm, E., Bourquard, T., Pengam, S., Teppaz, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.14.240093 · Cited by 18

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium

Vandercam, G., Simon, A., Scohy, A., Belkhir, L., Kabamba, B., Rodriguez‐Villalobos, H., & Yombi, J. C. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.09.018 · Cited by 17

COVID-19 and a Green Recovery?

Goenka, A., Liu, L., & Nguyen, M. (2021) · Economic Modelling · doi:10.1016/j.econmod.2021.105639 · Cited by 17

Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays

Tanis, J., Vancutsem, E., Piérard, D., Weets, I., Bjerke, M., Schiettecatte, J., & Geyter, D. D. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115313 · Cited by 17

Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility

Rosadas, C., Khan, M., Parker, E. L., Marchesin, F., Katsanovskaja, K., Sureda-Vives, M., Fernández, N., Randell, P. A., Harvey, R., Lilley, A., et al. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114475 · Cited by 17

Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain

Pérez‐Olmeda, M., Saugar, J. M., Fernández-García, A., Pérez‐Gómez, B., Pollán, M., Avellón, A., Pastor‐Barriuso, R., de Larrea, N. F., Martín, M., Cruz, I., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105130 · Cited by 18

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis

Ruiz, M. J., Siracusano, G., Cottignies-Calamarte, A., Tudor, D., Real, F., Zhu, A., Pastori, C., Capron, C., Rosenberg, A. R., Temperton, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842468 · Cited by 21

Modelling optimal lockdowns with waning immunity

Goenka, A., Liu, L., & Nguyen, M. (2022) · Economic Theory · doi:10.1007/s00199-022-01468-8 · Cited by 18

Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March–July 2020

Kaufman, H. W., Chen, Z., Meyer, W. A., & Wohlgemuth, J. G. (2020) · Population Health Management · doi:10.1089/pop.2020.0256 · Cited by 17

COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies

Yang, Y., Zhao, Y., Zhang, F., Zhang, L., & Li, L. (2020) · Aging and Disease · doi:10.14336/ad.2020.0903 · Cited by 18

Disease‐duration based comparison of subsets of immune cells in SARS CoV‐2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity

Kulkarni‐Munje, A., Palkar, S. H., Shrivastava, S., Lalwani, S. K., Mishra, A. C., & Arankalle, V. A. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.402 · Cited by 18

Reinfection in COVID-19: A scoping review

Pinto, L., Nanda, V., Sunavala, A., & Rodriques, C. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.02.010 · Cited by 20

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico

Montes-González, J. A., Zaragoza-Jiménez, C. A., Antonio‐Villa, N. E., Fermín‐Martínez, C. A., Ramírez‐García, D., Vargas‐Vázquez, A., Gutiérrez‐Vargas, R., García-Rodríguez, G., López‐Gatell, H., Valdés‐Ferrer, S. I., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1146059 · Cited by 19

A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an AAV hACE2 Mouse Model and non-human primatesPreprint

Guirakhoo, F., Kuo, L., Peng, J., Huang, J.-H., Kuo, B.-S., Lin, F., Liu, Y.-J., Liu, Z., Wu, G., Ding, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.30.399154 · Cited by 16

A Prospective Study on Rapidly Declining SARS‐CoV‐2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?

Nag, D. S., Chaudhry, R., Mishra, M., Rai, S., & Gupta, M. (2020) · Cureus · doi:10.7759/cureus.11845 · Cited by 16

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Favresse, J., Elsen, M., Eucher, C., Laffineur, K., Eeckhoudt, S. V., Nicolas, J., Gillot, C., Dogné, J.-M., & Douxfils, J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1736 · Cited by 16

SARS-CoV-2 Reinfection among Healthcare Workers in Mexico: Case Report and Literature Review

Garduño-Orbe, B., Sánchez-Rebolledo, J. M., Cortés-Rafael, M., García-Jiménez, Y., Perez-Ortiz, M., Mendiola-Pastrana, I. R., López‐Ortiz, E., & López-Ortiz, G. (2021) · Medicina · doi:10.3390/medicina57050442 · Cited by 16

Bilateral Ampiginous Choroiditis following Presumed SARS-CoV-2 Infection

Tom, E. S., McKay, K. M., & Saraf, S. S. (2021) · Case Reports in Ophthalmological Medicine · doi:10.1155/2021/1646364 · Cited by 16

The (apparent) antibody paradox in COVID-19

Ameratunga, R., Woon, S., Lea, E., Steele, R. H., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2044797 · Cited by 16

Relationship of anti-SARS-CoV-2 IgG antibodies with Vitamin D and inflammatory markers in COVID-19 patients

Latifi-Pupovci, H., Namani, S. A., Pajaziti, A., Ahmetaj‐Shala, B., Berisha, L. A., Kotori, A., Haxhibeqiri, V., Gegaj, V., & Bunjaku, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-09785-7 · Cited by 16

Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV

Donadeu, L., Tiraboschi, J. M., Scévola, S. C., Torija, A., Meneghini, M., Jouvé, T., Favà, A., Calatayud, L., Ardanuy, C., Cidraque, I., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003276 · Cited by 16

SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study

Brlić, P. K., Pavletić, M., Lerga, M., Krstanović, F., Matešić, M. P., Miklić, K., Malić, S., Mikša, L., Pajcur, M., Peruč, D., et al. (2022) · Viruses · doi:10.3390/v14091966 · Cited by 17

Elevated BMI reduces the humoral response to SARS‐CoV‐2 infection

Tong, Z. W. M., Sng, J. D. J., Carney, M., Cooper, L., Brown, S., Lineburg, K. E., Chew, K. Y., Collins, N., Ignacio, K., Airey, M., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1476 · Cited by 18

Diagnostic biologique de l’infection à Sars-CoV-2 : stratégies et interprétation des résultats

Hantz, S. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30313-0 · Cited by 16

Open government data, uncertainty and coronavirus: An infodemiological case study

Yiannakoulias, N. W., Slavik, C. E., Sturrock, S. L., & Darlington, J. C. (2020) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.113549 · Cited by 16

Classification under uncertainty: data analysis for diagnostic antibody testing

Patrone, P. N., & Kearsley, A. J. (2021) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqab007 · Cited by 17

Coronavirus Disease 2019 Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Positivity in a Large Survey of First Responders and Healthcare Personnel, May–July 2020

Akinbami, L. J., Petersen, L. R., Sami, S., Vuong, N., Lukacs, S. L., Mackey, L., Atas, J. G., & LaFleur, B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab080 · Cited by 16

Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP

Keshavarz, B., Wiencek, J. R., Workman, L. J., Straesser, M. D., Muehling, L. M., Canderan, G., Drago, F., Bonham, C. A., Sturek, J. M., Ramani, C., et al. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514203 · Cited by 16

Persistence of humoral response upon SARS‐CoV‐2 infection

Knies, A., Ladage, D., Braun, R. J., Kimpel, J., & Schneider, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2272 · Cited by 17

Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity

Wu, J., Liang, B.-Y., Fang, Y., Wang, H., Yang, X., Shěn, S., Chen, L., Li, S., Lu, S., Xiang, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722027 · Cited by 16

Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020

Flamand, C., Enfissi, A., Bailly, S., Sarmento, C. A., Beillard, E. J., Gaillet, M., Michaud, C., Servas, V., Clement, N., Perilhou, A., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009945 · Cited by 17

SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls

Goyal, A., Gupta, Y., Kalaivani, M., Praveen, P. A., Ambekar, S., & Tandon, N. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.009 · Cited by 16

Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests

Maine, G. N., Krishnan, S. M., Walewski, K., Trueman, J., Sykes, E., & Sun, Q. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113243 · Cited by 16

Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Choe, P. G., Hong, J., Park, J., Chang, E., Kang, C. K., Kim, N. J., Lee, C. H., Park, W. B., & Oh, M. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac099 · Cited by 16

Correction: Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/31554 · Cited by 16

Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases

Duthie, M. S., & Reed, S. G. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-11062-4 · Cited by 15

SARS-CoV-2 As an Inflammatory Cardiovascular Disease: Current Knowledge and Future Challenges

Shah, K., Hammond, M. E., Drakos, S. G., Anderson, J. L., Fang, J. C.-T., Knowlton, K. U., & Shaw, R. M. (2021) · Future Cardiology · doi:10.2217/fca-2020-0188 · Cited by 14

Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis

Anand, S., Montez‐Rath, M. E., Han, J., García, P., Cadden, L., Hunsader, P., KERSCHMANN, R. L., Beyer, P., Boyd, S. D., Chertow, G. M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0256 · Cited by 14

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

Adriaenssens, N., Scholtes, B., Bruyndonckx, R., Verbakel, J. Y. J., Sutter, A. D., Heytens, S., den Bruel, A. V., Desombere, I., Damme, P. V., Goossens, H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054688 · Cited by 14

Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2

Ameratunga, R., Woon, S.-T., Steele, R., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2074403 · Cited by 16

CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses

Noto, A., Joo, V., Mancarella, A., Suffiotti, M., Pellaton, C., Fenwick, C. W., Perreau, M., & Pantaleo, G. (2022) · Viruses · doi:10.3390/v14122665 · Cited by 14

Antibody correlates of protection against Delta infection after vaccination: A nested case-control within the UK-based SIREN study

Atti, A., Insalata, F., Carr, E. J., Otter, A. D., Foulkes, S., Wu, M., Cole, M. J., Linley, E., Semper, A. E., Brooks, T. J. G., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.07.007 · Cited by 15

Silent battles: immune responses in asymptomatic SARS-CoV-2 infection

Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 16

Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster

Goren, A., Cadegiani, F., Wambier, C. G., Vañó-Galván, S., Tosti, A., Shapiro, J., Mesinkovska, N. A., Ramos, P. M., Sinclair, R. D., Lupi, O., et al. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110439 · Cited by 15

Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests

Kline, D., Li, Z. R., Chu, Y., Wakefield, J. C., Miller, W. C., Turner, A. N., & Clark, S. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023947118 · Cited by 14

Sustainability of SARS-CoV-2 Induced Humoral Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over Six Months

Zheng, Y., Zhang, Q., Ali, A., Li, K., Shao, N., Zhou, X., Ye, Z., Chen, X., Cao, S., Cui, J., et al. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00360-4 · Cited by 15

Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut

Papasavas, P. K., Olugbile, S. O., Wu, U., Robinson, K. J., Roberts, A. L., O’Sullivan, D. M., McLaughlin, T., Mather, J., Steinberg, A. C., Orlando, R., et al. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.04.021 · Cited by 13

Practical guidance for clinical laboratories for SARS-CoV-2 serology testing

Charlton, C. L., Kanji, J. N., Tran, V., Kus, J. V., Gubbay, J. B., Osiowy, C., Robinson, J. L., Sekirov, I., DREBOT, M. A., Hatchette, T. F., et al. (2021) · Canada Communicable Disease Report · doi:10.14745/ccdr.v47i04a01 · Cited by 14

Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform

Chaudhury, S., Hutter, J. N., Bolton, J. S., Hakre, S., Mose, E., Wooten, A., O’Connell, W., Hudak, J. J., Krebs, S. J., Darden, J. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252628 · Cited by 15

Handheld Thermo-Photonic Device for Rapid, Low-Cost, and On-Site Detection and Quantification of Anti-SARS-CoV-2 Antibody

Thapa, D., Samadi, N., & Tabatabaei, N. (2021) · IEEE Sensors Journal · doi:10.1109/jsen.2021.3089016 · Cited by 15

ROS/RNS Balancing, Aerobic Fermentation Regulation and Cell Cycle Control – a Complex Early Trait (‘CoV-MAC-TED’) for Combating SARS-CoV-2-Induced Cell Reprogramming

Costa, J. H., Mohanapriya, G., Bharadwaj, R., Noceda, C., Thiers, K. L. L., Aziz, S. R., Srivastava, S., Oliveira, M., Gupta, K. J., Kumari, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673692 · Cited by 15

Immunology of SARS-CoV-2 infections and vaccines

Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14

Decisive conditions for strategic vaccination against SARS-CoV-2

Böttcher, L., & Nagler, J. (2021) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0066992 · Cited by 15

Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models

Li, D., Luan, N., Li, J., Zhao, H., Zhang, Y., Long, R., Jiang, G., Fan, S., Xu, X., Cao, H., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2002670 · Cited by 15

Antibody levels remain high to one-year’s follow-up after moderate and severe COVID-19, but not after mild cases

Kallaste, A., Kisand, K., Aart, A., Kisand, K. E., Peterson, P., & Lember, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.2018492 · Cited by 14

Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood

Campbell, C., Padmanabhan, N., Romero, D., Joe, J., Gebremeskel, M., Manjula, N., Wohlstadter, N., Wohlstadter, R., Goodwin, P., Quintero, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10484-6 · Cited by 14

Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2Preprint

Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3739808 · Cited by 15

Second Episode of COVID-19 in Health Professionals: Report of Two Cases

de Brito, C. A. A., Lima, P. M. A., de Brito, M. C. M., & de Oliveira, D. B. (2020) · International Medical Case Reports Journal · doi:10.2147/imcrj.s277882 · Cited by 15

SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare Professionals Working with Cancer Patients during the First Wave of the COVID-19 Pandemic

Favara, D. M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Döffinger, R., Ainsworth, N. L., & Corrie, P. G. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.04.005 · Cited by 13

Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test

da Silveira, M. F., Mesenburg, M. A., Dellagostin, O. A., de Oliveira, N. R., Maia, M. A. C., Santos, F. D. S., Vale, A. M., Menezes, A. M. B., Victora, G. D., Victora, C. G., et al. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101601 · Cited by 14

Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?

Dhawan, M. K., Saied, A. A., & Sharma, M. K. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100127 · Cited by 17

Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies

Zhao, T., Huang, X., & Shu, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2273155 · Cited by 14

Implications of SARS-CoV-2-Associated Myocarditis in the Medical Evaluation of Athletes

Raukar, N. P., & Cooper, L. T. (2020) · Sports Health A Multidisciplinary Approach · doi:10.1177/1941738120974747 · Cited by 15

Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders—The COVID-19 Arapahoe SErosurveillance Study (CASES) Project

Sabourin, K. R., Schultz, J. S., Romero, J., Lamb, M. M., Larremore, D. B., Morrison, T. E., Frazer‐Abel, A. A., Zimmer, S. M., Kedl, R. M., Jaenisch, T., et al. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002099 · Cited by 13

Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK

Shrotri, M., Harris, R., Rodger, A. J., Planche, T., Sanderson, F., Mahungu, T. W., McGregor, A. C., Heath, P. T., The LondonCOVID Group, Brown, C. S., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2704.204554 · Cited by 13

Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG

Jamiruddin, M. R., Haq, M. A., Tomizawa, K., Kobatake, E., Mie, M., Ahmed, S., Khandker, S. S., Ali, T., Jahan, N., Oishee, M. J., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s313188 · Cited by 14

SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study

Meylan, S., Dafni, U. G., Lamoth, F., Tsourti, Z., Lobritz, M. A., Regina, J., Bressin, P., Senn, L., Grandbastien, B., André, C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049232 · Cited by 14

Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection

Wisnivesky, J. P., Stone, K., Bagiella, E., Doernberg, M., Mendu, D. R., Lin, J. J., & Kale, M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07057-0 · Cited by 13

Multiple immune function impairments in diabetic patients and their effects on COVID-19

Lu, Z., Yu, W., & Sun, Y. T. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i24.6969 · Cited by 13

Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using TigraTest® SARS-CoV-2 ELISPOT kit

Poteryaev, D. A., Abbasova, S. G., Ignatyeva, P. E., Strizhakova, O. M., Колесник, С. В., & Авгатович, Х. Р. (2021) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2021-21-3-178-192 · Cited by 15

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2

Ukey, R., Bruiners, N., Mishra, H. K., Mishra, P. K., McCloskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02252-0 · Cited by 16

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

Sarjomaa, M., Diep, L. M., Zhang, C., Tveten, Y., Reiso, H., Thilesen, C., Nordbø, S. A., Berg, K. K., Aaberge, I. S., Pearce, N. E., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264667 · Cited by 15

Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination

Taus, E., Hofmann, C., Ibarrondo, F. J., Gong, L. S., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Kitchen, S. G., Ferbas, K. G., Tobin, N. H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100594 · Cited by 14

Identification of HLA-A2 restricted CD8+ T cell epitopes in SARS-CoV-2 structural proteins

Deng, J., Pan, J., Qiu, M., Mao, L., Wang, Z., Zhu, G., Gao, L., Su, J., Hu, Y., Luo, O. J., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ma0621-020r · Cited by 14

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Gelibter, S., Orrico, M., Filippi, M., & Moiola, L. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102775 · Cited by 14

COVID-19: The Pseudo-Environment and the Need for a Paradigm Change

Stein, R. A., Ometa, O., & Broker, T. R. (2021) · GERMS · doi:10.18683/germs.2021.1283 · Cited by 16

Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States

Killerby, M. E., Rasheed, M. A. U., Tamin, A., Harcourt, J. L., Abedi, G. R., Lu, X., Kujawski, S. A., Shah, M. M., Kirking, H. L., Gold, J. A. W., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab125 · Cited by 12

Assay dependence of long-term kinetics of SARS-CoV-2 antibodies

Schallier, A., Baets, S. D., Bruyne, D. D., Dauwe, K., Herpol, M., & Couck, P. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115403 · Cited by 11

Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients

Garanina, E. E., Hamza, S., Stott-Marshall, R. J., Martynova, E. V., Markelova, M., Davidyuk, Y. N., Shakirova, V. G., Kaushal, N., Baranwal, M., Хаертынова, И. М., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.842232 · Cited by 13

Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation

Azamor, T., Horbach, I. S., Cunha, D. B. E., Melgaço, J. G., da Silva, A. M. V., Tubarão, L. N., Azevedo, A. D. S., Santos, R. T., Alves, N. D. S., Machado, T. L., et al. (2022) · Viruses · doi:10.3390/v14091916 · Cited by 14

Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months

Lea, C. S., Simeonsson, K. L., Kipp, A. M., McNeill, C., Wilcox, L., Irish, W. D., Morris, H., Diaz, O., Fallon, J. T., & Roper, R. L. (2022) · Vaccines · doi:10.3390/vaccines10091532 · Cited by 13

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19

Chen, J., Huang, R., Nie, Y., Wen, X., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00327-x · Cited by 12

Renal Infarcts—A Perplexing Case in the Middle of the COVID-19 Pandemic

Plouffe, B., Hooren, T. A. V., Barton, M., Nashid, N., Demirkaya, E., Norozi, K., Rachinsky, I., Delport, J., Knauer, M. J., Tole, S., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.669453 · Cited by 13

SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study

Science, M. E., Bolotin, S., Silverman, M. E., Nadarajah, J., Maguire, B. R., Parekh, R. S., McGeer, A., Schwartz, K. L., Alexander, L. E. C., Allen, U., et al. (2021) · CMAJ Open · doi:10.9778/cmajo.20210044 · Cited by 13

Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology

Ochola, L. B., Ogongo, P., Mbugua, S. M., Gitaka, J., & Suliman, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.005 · Cited by 13

SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition

Limoges, M.-A., Quenum, A., Chowdhury, M. M. H., Rexhepi, F., Namvarpour, M., Akbari, S. A., Rioux‐Perreault, C., Nandi, M., Lucier, J., Lemaire‐Paquette, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223936 · Cited by 14

Endemic Non–SARS-CoV-2 Human Coronaviruses in a Community-Based Australian Birth Cohort

Grimwood, K., Lambert, S. B., & Ware, R. S. (2020) · PEDIATRICS · doi:10.1542/peds.2020-009316 · Cited by 14

Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors

Annen, K., Morrison, T. E., DomBourian, M. G., McCarthy, M. K., Huey, L., Merkel, P. A., Andersen, G., Schwartz, E., & Knight, V. (2021) · Transfusion · doi:10.1111/trf.16261 · Cited by 13

Legend of the Sentinels: Development of Lung Resident Memory T Cells and Their Roles in Diseases

Qian, Y., Zhu, Y., Li, Y., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624411 · Cited by 14

Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine

Selvavinayagam, S. T., Yong, Y. K., Tan, H. Y., Zhang, Y., Subramanian, G., Rajeshkumar, M., Kalaivani, V., Jayapal, P., Narayanasamy, K., Ramesh, D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.887974 · Cited by 11

Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19

Bölke, E., Matuschek, C., & Fischer, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027051 · Cited by 95

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65

Neutralizing Antibodies Against SARS-CoV-2—Important Questions, Unclear Answers

Katz, M. H. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4624 · Cited by 6

Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient

Yin, S., Tong, X., Huang, A., Shen, H., Li, Y., Liu, Y., Wu, C., Huang, R., & Chen, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.076 · Cited by 26

Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Xia, W., Li, M., Wang, Y., Kazis, L. E., Berlo, K., Melikechi, N., & Chiklis, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96171-4 · Cited by 32